Back to Sectors

CTXR

Citius Pharmaceuticals, Inc.
2 filings tracked
healthcarebiotechnologyMICRO (<$300M)

Signal Magnitude Chart

BEARISH | 90% | 5/15/2026 | earnings missNEUTRAL | 70% | 5/15/2026 | capital raiseBULLISH | 80% | 5/15/2026 | margin expansionBEARISH | 60% | 5/15/2026 | regulatory actionBEARISH | 90% | 5/15/2026 | earnings missNEUTRAL | 70% | 5/15/2026 | capital raiseBULLISH | 80% | 5/15/2026 | margin expansionBEARISH | 60% | 5/15/2026 | regulatory actionMay 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

bearishMay 15

Net loss of $37.5 million over six months despite initial revenue generation.

earnings miss
90%
neutralMay 15

Secured $25M loan facility and multiple equity offerings to extend runway to Nov 2026.

capital raise
70%
bullishMay 15

Achieved 80% gross margins on initial LYMPHIR product revenues.

margin expansion
80%
bearishMay 15

Received Nasdaq non-compliance notices for minimum bid price requirements.

regulatory action
60%
bearishMay 15

Net loss of $37.5 million over six months despite initial revenue generation.

earnings miss
90%
neutralMay 15

Secured $25M loan facility and multiple equity offerings to extend runway to Nov 2026.

capital raise
70%
bullishMay 15

Achieved 80% gross margins on initial LYMPHIR product revenues.

margin expansion
80%
bearishMay 15

Received Nasdaq non-compliance notices for minimum bid price requirements.

regulatory action
60%

Filing History

10-QMay 15, 2026

The latest 10-Q filing presents a stark contrast between operational success and financial instability. On one hand, the commercial validation of LYMPHIR is undeniable, with strong margins and rapid institutional uptake providing a proof-of-concept for the company's revenue potential. On the other hand, the sheer scale of the operating losses and the urgency of the capital raises highlight a company fighting for survival against a ticking clock. The $19.7 million one-time CMO termination fee served as a significant drag on the quarter, but the underlying burn rate remains high. Investors are now faced with a high-stakes trade-off: the potential for LYMPHIR to scale rapidly into a blockbuster-level revenue stream versus the very real risk of insolvency or extreme dilution before that scale is achieved. The success of the company now hinges on its ability to convert early institutional interest into sustainable cash flow and to successfully navigate the restrictive terms of its new $25 million loan facility. The window of opportunity is narrow, extending only to late 2026.